The investment fund Columbus Venture Patners and Asklepios will invest up to €9M in the bio sector in Gipuzkoa.

18/09/2017
Diego Gutiérrez
The investment fund Columbus Venture Patners and Asklepios will invest up to €9M in the bio sector in Gipuzkoa.
The venture capital fund Columbus and the US company Asklepios set up the joint venture Viralgen to invest in the opening of a viral vector plant in San Sebastian.

Columbus Venture Partners is a Valencian venture capital fund specialising in high-growth investments in the Spanish bio-based industry. The fund had been involved for several years with AsklepiosThe aim of the meeting was to identify ways of carrying out joint projects.

In this new project Columbus provides the investment, between €7M and €9M, and Asklepios the know-how, forming a 50/50 joint venture. This has given rise to the Viralgen joint venture, with the aim of investing in a new plant for the production of adeno-associated viral vectors in the Mlramon Parkin San Sebastian. These vectors, used in rare diseases of genetic origin, carry the correct gene that is integrated into the diseased cell, correcting its malfunction.

The investment of this new joint venture could turn the Miramón Park in Gipuzkoa into a leading biotech hub. The aim of the new plant is to reduce the need for European biotechs for these viral vectors, the production of which is a very complex and time-consuming process. In fact, there is a waiting list of up to two years for some products required in clinical trials. When fully operational, the plant will have three production lines, plus laboratories, and will employ between 40 and 50 people.

Columbus has announced its intention to hold for no more than ten years, with a three-fold return for its investors. The fund, led by Javier García and Damiá Tormo (creators of Bioncotech and Artax), has portfolio companies such as Aura Bioscience, Polypeptide Therapeutic and VivetTherapeutics, among others.

Funding rounds in the biotech sector in Spain 2016-17
 
Other posts that may interest you

Spanish biotech gets backing from investors: 4 companies have raised more than €3M in May

If you are looking for investors, you want to buy or selling a companyplease contact us. Abra-Invest has a team of experts in each area at your disposal. Call +34 946424142 or fill in the contact form.

Lastest news

The State of Technology M&A in Spain | October 2026 analysis

En octubre de 2026 hubo 37 operaciones de M&A tecnológico en España: 16 fueron adquisiciones corporativas, inversiones de private equity, fusiones o tomas de participación, y 21 fueron rondas de venture capital. El 62,2% de las operaciones (23 de 37) fueron...

Webinar | How much does your business depend on you?

IMPORTANT INFORMATION: Registration for and participation in the webinars are completely anonymous to third parties. If, for a month, you were unable to have a say in important decisions, what would happen in your company? Your company can grow, be profitable and have good...

Notable technology M&A deals in Spain | September 2026 Analysis

Technology M&A in Spain totalled 61 identified transactions by the end of September 2026, the highest figure in the monthly series we have been publishing since May. Of these, 41 were acquisitions, private equity investments, asset purchases, joint ventures or takeovers...

Baker Tilly advises Invelon on the acquisition of byAR

In September 2026, Invelon, a Spanish technology company specialising in virtual, augmented and mixed reality, completed the acquisition of a majority stake in byAR, a Portuguese company specialising in museum exhibitions and the development of spaces...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?